| Rheumatoid Arthritis |
1 |
1 |
| Thromboembolism |
0 |
0.63 |
| Arthritis |
0 |
0.61 |
| Biologic Therapy |
0 |
0.41 |
| Cancer |
0 |
0.41 |
| Europe |
0 |
0.41 |
| Cardiovascular Risk Management |
0 |
0.25 |
| Cerebrovascular Accident |
0 |
0.23 |
| Adverse Effects |
0 |
0.2 |
| Deep Venous Thrombosis |
0 |
0.2 |
| Heart |
0 |
0.2 |
| Medical Life |
0 |
0.2 |
| Smoking |
0 |
0.2 |
| Students |
0 |
0.2 |
| Vein |
0 |
0.2 |
| Patient Safety |
0 |
0.17 |
| Tobacco Cessation |
0 |
0.17 |
| Venous Thromboembolism (VTE) |
0 |
0.17 |
| Thrombus |
0 |
0.14 |
| Tumor Necrosis Factor-Alpha |
0 |
0.14 |
| Blood |
0 |
0.1 |
| Clinical Research |
0 |
0.1 |
| Face |
0 |
0.1 |
| Fellowship |
0 |
0.1 |
| Geriatrics |
0 |
0.1 |
| Grant |
0 |
0.1 |
| Infarction |
0 |
0.1 |
| Jobs |
0 |
0.1 |
| Lung |
0 |
0.1 |
| Salary and Compensation |
0 |
0.1 |
| Thrombosis |
0 |
0.1 |
| Tumor |
0 |
0.1 |
| Healthcare and Medical Technology |
0 |
0.09 |
| Myocardial Infarction (MI) |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.09 |